Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification.
Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification.
复制标题
作者：
Prior studies have shown that patients whose tumor overexpresses Her2 at 3+ level by immunohistochemistry (IHC) fare better than those whose tumor overexpresses Her2 at 2+ level (with ERBB2 amplified). Therefore, it would be important to compare the outcome of patients whose tumor expresses Her2 at 2+ level but further classify by gene amplification studies as positive or negative. We, retrospectively, identified patients with advanced gastroesophageal adenocarcinoma who had Her2 2+ by IHC and all of them had a gene amplification test for ERBB2 (FISH). All patients received first line therapy and trastuzumab was added according to Her2 status. We assessed the overall survival (OS), progression free survival (PFS), and overall response rate (ORR) of the entire cohort and compared Her2 positive tumor patients’ outcomes with Her2 negative tumor patients’ outcomes. All patients had treatment response assessments and follow ups at our institution. We identified 87 patients whose tumors expressed Her2 at 2+ level. 51 (58.6%) were Her2 negative and 36 (41.4%) were Her2 positive by FISH. The median OS for the entire group was 26 months (95% CI: 16.6 – 37.6). The median OS for Her2 positive or negative tumor patients was similar (p=0.70). The median PFS was for the entire cohort was 12.2 months (95% CI: 9.7 – 19.3 months). The median PFS according to the Her2 status was similar (p=0.60). There was no statistically significant difference in the ORR between the two groups. Our data suggest that patients with Her2 positivity or negativity when tumors have lower Her2 protein expression (2+ by IHC) have similar clinical outcomes. Further research is warranted in this cohort.
登录
查看更多内容
影响因子：
7.5
作者：
Reichelt, Uta;Duesedau, Peer;Sauter, Guido
通讯作者：
Sauter, Guido
影响因子：
45.3
作者：
Stroes, Charlotte, I;Schokker, Sandor;van Laarhoven, Hanneke W. M.
通讯作者：
van Laarhoven, Hanneke W. M.
影响因子：
45.3
作者：
Hecht, J. Randolph;Bang, Yung-Jue;Slamon, Dennis
通讯作者：
Slamon, Dennis
基于列线图的接受一线化疗的晚期食管胃腺癌患者的生存预测：曲妥珠单抗时代的一项多中心前瞻性研究。
影响因子：
8.8
作者：
Custodio A;Carmona-Bayonas A;Jiménez-Fonseca P;Sánchez ML;Viudez A;Hernández R;Cano JM;Echavarria I;Pericay C;Mangas M;Visa L;Buxo E;García T;Rodríguez Palomo A;Álvarez Manceñido F;Lacalle A;Macias I;Azkarate A;Ramchandani A;Fernández Montes A;López C;Longo F;Sánchez Bayona R;Limón ML;Díaz-Serrano A;Hurtado A;Madero R;Gómez C;Gallego J
通讯作者：
Gallego J
影响因子：
50.5
作者：
Tanner, M;Hollmén, M;Isola, J
通讯作者：
Isola, J